MDxHealth (NASDAQ:MDXH) Trading 4.5% Higher

MDxHealth SA (NASDAQ:MDXHGet Rating)’s stock price traded up 4.5% during trading on Thursday . The company traded as high as $8.20 and last traded at $8.20. 1,397 shares traded hands during trading, a decline of 36% from the average session volume of 2,176 shares. The stock had previously closed at $7.85.

Wall Street Analyst Weigh In

Separately, BTIG Research increased their target price on shares of MDxHealth from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Friday, August 26th.

MDxHealth Price Performance

The stock’s 50-day moving average is $7.10 and its 200 day moving average is $7.50. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.28 and a current ratio of 2.38.

MDxHealth (NASDAQ:MDXHGet Rating) last posted its quarterly earnings results on Thursday, August 25th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.15). The business had revenue of $6.90 million for the quarter. As a group, equities analysts anticipate that MDxHealth SA will post -2.24 EPS for the current fiscal year.

About MDxHealth

(Get Rating)

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications.

Featured Stories

Receive News & Ratings for MDxHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDxHealth and related companies with's FREE daily email newsletter.